Figure 5.

Injection of G-MDSCs from patients at day 28 into a humanized mouse model. (A) Protocol for establishing aGvHD model. Granulocytic myeloid-derived suppressor cells (G-MDSCs) collected from the patients at day 28 were injected into the mice with PBMCs from the related donors. (B) An enlarged spleen has been observed in the co-administration group. (C) Representative histology of the target organs harvested from the G-MDSCs alone control group, PBMC alone control group, and co-administration group. (D) Co-administration of G-MDSCs and PBMCs resulted in a notable decrease in the survival rate of mice (n=27). (E) T cell subsets were detected in the peripheral blood of mice once the proportion of human cells exceeded 20% (n=14). *p Th22 cells= 0.0313, Th17 cells=0.0469.